Compositions and methods related to the treatment of acute kidney injury (AKI) through the pharmaceutical manipulation of calcium signaling are disclosed. Such compositions and methods may be used to reduce inflammatory responses that may lead to AKI, or the progression of AKI to CKD.

The invention relates to self-assembled organosilane- and small molecule drug-containing coatings for resorbable medical implant devices. The coatings can be prepared from precursor compositions containing an organosilane and a small molecule drug, and can be applied to substrates. Prior to applying the coatings, the surfaces of the substrates can be pretreated. The coatings can be functionalized with a binding compound that is coupled with an active component. The coatings can be applied using various techniques and apparatus, more particularly, by a deep-coating process conducted at ambient conditions.

Compositions and methods for inducing immune tolerance to proteins and subsequence administration of the proteins are disclosed. Compositions comprise proteins complexed with liposomes comprising PS and PC, wherein at least part of the PS is present as lyso-PS.

Compositions and methods for inducing immune tolerance to proteins and subsequence administration of the proteins are disclosed. Compositions comprise proteins complexed with liposomes comprising PS and PC, wherein at least part of the PS is present as lyso-PS.

The present invention is directed to a combination therapy involving a type II anti-CD20 antibody and a selective Bcl-2 inhibitor for the treatment of a patient suffering from cancer, particularly, a CD20-expressing cancer.

The present invention is directed to a combination therapy involving a type II anti-CD20 antibody and a selective Bcl-2 inhibitor for the treatment of a patient suffering from cancer, particularly, a CD20-expressing cancer.

The present invention relates to a cyclic polysaccharide compound and particle comprising a plurality of said cyclic polysaccharide compounds and one or more agent, wherein the plurality of cyclic polysaccharide compounds form a hollow sphere, and the one or more agent is encapsulated within the hollow sphere; and wherein the one or more agent is non-covalently associated with the cyclic polysaccharide compound, optionally further comprising a surfactant. The particles may comprise one or more additional drug. The invention further relates to pharmaceutical, cosmetic, or nutraceutical use of the particles.

The present invention relates to a cyclic polysaccharide compound and particle comprising a plurality of said cyclic polysaccharide compounds and one or more agent, wherein the plurality of cyclic polysaccharide compounds form a hollow sphere, and the one or more agent is encapsulated within the hollow sphere; and wherein the one or more agent is non-covalently associated with the cyclic polysaccharide compound, optionally further comprising a surfactant. The particles may comprise one or more additional drug. The invention further relates to pharmaceutical, cosmetic, or nutraceutical use of the particles.

The present invention relates to a cyclic polysaccharide compound and particle comprising a plurality of said cyclic polysaccharide compounds and one or more agent, wherein the plurality of cyclic polysaccharide compounds form a hollow sphere, and the one or more agent is encapsulated within the hollow sphere; and wherein the one or more agent is non-covalently associated with the cyclic polysaccharide compound, optionally further comprising a surfactant. The particles may comprise one or more additional drug. The invention further relates to pharmaceutical, cosmetic, or nutraceutical use of the particles.

The present invention relates to the role of purinergic receptors and ATP in T cell activation and autocrine system signaling. In one embodiment, the present invention provides a method of preventing or treating diabetes by administering a therapeutically effective inhibitor of ATP to a subject. In another embodiment, the present invention provides a method of preventing or treating fibrosis by administering a P2X7R soluble fusion protein. In another embodiment, the present invention provides a method of preventing or treating graft rejection by administering an inhibitor of P2X receptor signaling.